Literature DB >> 12009284

Virosome-mediated delivery of protein antigens to dendritic cells.

Laura Bungener1, Karine Serre, Liesbeth Bijl, Lee Leserman, Jan Wilschut, Toos Daemen, Patrick Machy.   

Abstract

Virosomes are reconstituted viral membranes in which protein can be encapsulated. Fusion-active virosomes, fusion-inactive virosomes and liposomes were used to study the conditions needed for delivery of encapsulated protein antigen ovalbumin (OVA) to dendritic cells (DCs) for MHC class I and II presentation. Fusion-active virosomes, but not fusion-inactive virosomes, were able to deliver OVA to DCs for MHC class I presentation at picomolar OVA concentrations. Fusion activity of virosomes was not required for MHC class II presentation of antigen. Therefore, virosomes are an efficient system for delivery of protein antigens for stimulation of both helper and CTL responses.

Mesh:

Substances:

Year:  2002        PMID: 12009284     DOI: 10.1016/s0264-410x(02)00103-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

2.  The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.

Authors:  Takehisa Hebishima; Eiji Yuba; Kenji Kono; Shin-Nosuke Takeshima; Yoshihiro Ito; Yoko Aida
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

3.  Biodistribution and toxicity of epitope-functionalized dextran iron oxide nanoparticles in a pregnant murine model.

Authors:  Amir Bolandparvaz; Natalia Vapniarsky; Rian Harriman; Kenneth Alvarez; Jasmeen Saini; Zexi Zang; Judy Van De Water; Jamal S Lewis
Journal:  J Biomed Mater Res A       Date:  2020-02-26       Impact factor: 4.396

4.  Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA.

Authors:  Jørgen de Jonge; Johanna M Leenhouts; Marijke Holtrop; Pieter Schoen; Peter Scherrer; Pieter R Cullis; Jan Wilschut; Anke Huckriede
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

Review 5.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

6.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

7.  Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.

Authors:  Shinobu Watarai; Tana Iwase; Tomoko Tajima; Eiji Yuba; Kenji Kono
Journal:  ScientificWorldJournal       Date:  2013-02-04

8.  Improved antigen cross-presentation by polyethyleneimine-based nanoparticles.

Authors:  Jian Chen; Zhengrong Li; Hong Huang; Yanzhu Yang; Qian Ding; Junhua Mai; Wei Guo; Yuhong Xu
Journal:  Int J Nanomedicine       Date:  2011-01-06

Review 9.  Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.

Authors:  Marine L B Hillaire; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Biomed Biotechnol       Date:  2011-10-05

10.  Mechanisms of action of adjuvants.

Authors:  Sunita Awate; Lorne A Babiuk; George Mutwiri
Journal:  Front Immunol       Date:  2013-05-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.